BRIEF-Achieve Life Sciences Says Cytisinicline NDA Submission To FDA Planned For June 2025

Reuters
22 Apr
BRIEF-Achieve Life Sciences Says Cytisinicline NDA Submission To FDA Planned For June 2025

April 21 (Reuters) - Achieve Life Sciences Inc ACHV.O:

  • ACHIEVE LIFE SCIENCES ANNOUNCES CYTISINICLINE PHASE 3 ORCA-3 TRIAL PUBLICATION ON SMOKING CESSATION IN JAMA INTERNAL MEDICINE

  • ACHIEVE LIFE SCIENCES INC - CYTISINICLINE NDA SUBMISSION TO FDA PLANNED FOR JUNE 2025

Source text: ID:nGNX6nrvpC

Further company coverage: ACHV.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10